What is the price of Marizyme, Inc. (MRZM)

The price of Marizyme, Inc. (MRZM) is $0.0003

What is the market cap of Marizyme, Inc. (MRZM)

The market cap of Marizyme, Inc. (MRZM) is $39.54K

Marizyme, Inc. (MRZM) Operating Margin

Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.

Year	Operating Margin	Change
Not enough data for the provided dates.

Year

Operating Margin

Change

Not enough data for the provided dates.

Company	Operating Margin	Operating Margin Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	38.97%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR
UCB S.A. UCB.BR	31.23%	-	BE

Company

Operating Margin

Operating Margin Difference

Country